Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715057 | 0.85 | KDM4E (0.48) | KDM4ESIGMAR1KMT2ANPC1HPGD | |
| SCHEMBL1309983 | 0.80 | CXCR4 (0.44) | KDM4EMEN1KMT2ATDP1NPC1 | |
| SCHEMBL182214 | 0.80 | KDM4E (0.59) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL5593717 | 0.77 | KDM4E (0.56) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL4868685 | 0.77 | ALDH1A1 (0.50) | KDM4ESIGMAR1NPC1ALDH1A1RAB9A | |
| SCHEMBL10425868 | 0.76 | SIGMAR1 (0.73) | SIGMAR1MEN1KMT2ATDP1NPC1 | |
| SCHEMBL29169546 | 0.76 | PTGS2 (0.57) | KDM4EKMT2ANPC1ALDH1A1HPGD | |
| SCHEMBL9790769 | 0.76 | PTGS2 (0.57) | KDM4EKMT2ANPC1ALDH1A1HPGD | |
| SCHEMBL4595 | 0.76 | PTGS2 (0.57) | KDM4EKMT2ANPC1ALDH1A1HPGD | |
| SCHEMBL31285559 | 0.76 | KDM4E (0.55) | KDM4ENPC1ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859580-B2 | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | HSD3B1, CYP11B1, HSD11B1 | KDM4E 1399/4885SIGMAR1 287/4885MEN1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.